Approval · Notice of Compliance 49 · 2004
ATACAND: Notice of Compliance 49
Issued January 28, 2004
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 49
- Date
- January 28, 2004
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update product monograph re: first-line treatment
- Therapeutic class
- Angiotensin ii at1 receptor blocker & angiotensin ii at1 receptor blocker + diuretic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ATACAND | Not yet assigned | — |
| ATACAND PLUS | Not yet assigned | — |
Medicinal ingredients
- CANDESARTAN CILEXETIL 4 MG per TAB
- CANDESARTAN CILEXETIL 8 MG per TAB
- CANDESARTAN CILEXETIL 16 MG per TAB
- HYDROCHLOROTHIAZIDE 12.5 MG per TAB